Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny device could fix leaky heart valves without cutting chest open

NCT ID NCT07671820

Disease control Sponsor: Lifecord Otd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This early trial tests a new device called Anchord that repairs leaky mitral valves without open-heart surgery. It will include 5 people with severe valve leakage who are too high-risk for standard surgery. The goal is to see if the device is safe and can reduce the leak, improving symptoms like shortness of breath.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Anchord Mitral Chordal Repair device
What this could lead to
If it works, this could offer a less invasive option for people with leaky heart valves who are too high-risk for open-heart surgery.
What could go wrong
This is a very early first-in-human trial with only 5 participants, so results may not apply broadly. The device could fail to reduce the leak or cause complications like infection or device movement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 5 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Severe symptomatic degenerative mitral regurgitation (grade 3+) * High surgical risk for open-heart mitral valve repair or replacement * Suitable anatomy for transcatheter chordal repair as determined by the treating physician * Ability to undergo required echocardiographic and fluoroscopic imaging * Ability to provide informed consent Exclusion Criteria: * Active endocarditis or systemic infection * Severe left ventricular dysfunction (LVEF \<30%) * Significant non-mitral valvular disease requiring intervention * Severe mitral annular calcification (MAC) * Presence of intracardiac or femoral venous thrombus or thrombus in the inferior vena cava * Cerebrovascular events (TIA, CVA) or thromboembolic events within the previous 6 months. * Renal insufficiency * Inability to undergo required imaging or access * Inability to tolerate standard anticoagulation or antithrombotic regimen * Rheumatic mitral valve disease * Co-morbid condition limiting life expectancy or study completion * Pregnancy * Participation in another clinical trial * Previous device treatment for MR.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mitral regurgitation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mitral valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mitral regurgitation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.